Skip to main content
SpringerLink
Log in

Colchicin zur Behandlung der Gicht

Pro-Statement

Colchicine for the management of gout

Pro-statement

  • Pro und Contra
  • Published:
rheuma plus Aims and scope

Zusammenfassung

Colchicin ist eine pharmakologische Substanz, die bei Gicht sowohl in der Therapie des akuten Anfalls als auch in der Anfallsprophylaxe eingesetzt werden kann. Colchicin ist Bestandteil aller internationalen Empfehlungen zum Gichtmanagement und ist – wenn auch ein schon seit Jahrtausenden bekanntes pflanzliches Heilmittel – aus dem modernen therapeutischen Armamentarium der Gichttherapie nicht weg zu denken. Weitere rheumatologische Einsatzgebiete sind das familiäre Mittelmeerfieber und der Morbus Behcet. Colchicin wird aber auch bei der akuten und rezidivierenden Pericarditis eingesetzt, hat sich in Studien als günstig in der Prävention von Vorhofflimmern herausgestellt und zählt zu den Phytochemikalien, die offensichtlich ein antikanzerogenes Potential haben.

Abstract

Colchicine is used in the management of acute gout flares as well as in flare prophylaxis. Colchicine is part of all international guidelines concerning the management of gout. Although being a well known herbal remedy since ages, Colchicin is still an essential part of the up to date therapeutic options. It is also used for the management of familial Mediterranean fever, as well as Morbus Behcet. Colchicine is very efficient in acute and chronic pericarditis and has proven its effectiveness in the prevention of atrial flattering. Furthermore, it is part of a group of anticancerogenic phytochemical products.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Kuo CR et al (2015) Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 11(11):649–662

    Article  PubMed  Google Scholar 

  2. Feig DI et al (2008) Uric acid and cardiovascular risk. N Eng J Med 359(17):1811–1821

    Article  CAS  Google Scholar 

  3. Kuo CF et al (2016) Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis 75(1):210–217

    Article  PubMed  Google Scholar 

  4. Choi HK et al (2007) Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 57(1):109–115

    Article  PubMed  Google Scholar 

  5. Fisher MC et al (2017) The unclosing premature mortality gap in gout; a general population-based study. Ann Rheum Dis 76:1289–1284

    Article  PubMed  Google Scholar 

  6. Kuo CF, Luo SF (2017) Gout: risk of premature death in gout unchanged for years. Nat Rev Rheumatol 13(4):200–201

    Article  PubMed  Google Scholar 

  7. Sautner J (2014) Diagnosis and management of gout in Austria. Survey of current practice considering the EULAR recommendations. Z Rheumatol 73(9):836–842

    Article  CAS  PubMed  Google Scholar 

  8. Richette P et al (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76:29–42

    Article  CAS  PubMed  Google Scholar 

  9. Hui M et al (2017) The British Society for Rheumatology Guideline for the management of gout. Rheumatology 56:1246

    Article  PubMed  Google Scholar 

  10. Kiltz U et al (2017) Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis 76:1765–1770

    Article  Google Scholar 

  11. Kiltz U et al (2017) Evidence-based recommendations for diagnostics and treatment of gouty arthritis in the specialist sector: S2e guidelines of the German Society of Rheumatology in cooperation with the AWMF. Z Rheumatol 76(2):118–124

    Article  CAS  PubMed  Google Scholar 

  12. Sivera F et al (2014) Multination evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 73(2):328–335

    Article  PubMed  Google Scholar 

  13. Khanna D et al (2012) 2012 American College of Rheumatology guidelines for management of gout. Part: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64:1431–1446

    Article  CAS  Google Scholar 

  14. Sautner J et al (2014) Austrian 3e-recommendations for diagnosis and management of gout 2013. Wien Klin Wochenschr 126(3–4):79–89

    Article  PubMed  Google Scholar 

  15. Leung YY et al (2015) Colchicine – update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum 45(3):341–350

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Angelidis C et al (2018) Colchicine pharmacokinetics and mechanism of action. Curr Pharm Des. https://doi.org/10.2174/1381612824666180123110042

    Google Scholar 

  17. Terkeltaub RA et al (2010) High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 62(4):1060–1068

    Article  CAS  PubMed  Google Scholar 

  18. Wortmann RL et al (2010) Effect of prophylaxis on gout flares after the initiation of urate – lowering therapy: analysis of data from three phase III trials. Clin Ther 32(14):2386–2397

    Article  CAS  PubMed  Google Scholar 

  19. Becker MA et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353:2450–2461

    Article  CAS  PubMed  Google Scholar 

  20. Schumacher HR Jr et al (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59:1540–1548

    Article  CAS  PubMed  Google Scholar 

  21. Becker MA et al (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 12:R63

    Article  PubMed  PubMed Central  Google Scholar 

  22. Zemer D et al (1986) Colchicine in the prevention and treatment of the amyloidosis in familial Mediterranean fever. N Eng J Med 314(16):1001–1005

    Article  CAS  Google Scholar 

  23. Martinez GJ et al (2017) The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2017.12.027

    PubMed  Google Scholar 

  24. Deftereos S et al (2012) Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J Am Coll Cardiol 60(18):1790–1796

    Article  CAS  PubMed  Google Scholar 

  25. Bessissow A et al (2017) Colchicine for prevention of perioperative atrial fibrillation in patients undergoing lung resection surgery: a pilot randomized controlled study. Eur J Cardiothorac Surg. https://doi.org/10.1093/ejcts/ezx422

    PubMed  Google Scholar 

  26. Lazaros G et al (2018) The role of colchicine in pericardial syndromes. Curr Pharm Des. https://doi.org/10.2174/1381612824666180116101823

    PubMed  Google Scholar 

  27. Nidorf SM et al (2013) Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 29(4):404–410

    Article  Google Scholar 

  28. Solomon DH et al (2016) Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis 75:1674–1679

    Article  CAS  PubMed  Google Scholar 

  29. Hemkens LG et al (2016) Colchicine for prevention of cardiovascular events. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011047.pub2

    PubMed  Google Scholar 

  30. Vaidya K et al (2017) Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a CT coronary angiography study. Jacc Cardiovasc Imaging. https://doi.org/10.1016/j.jcmg.2017.08.013

    Google Scholar 

  31. Tsivqoulis G et al (2018) The role of colchicine in the prevention of cerebrovascular ischemia. Curr Pharm Des. https://doi.org/10.2174/1381612824666180116100310.. [Epub ahead of print]

    Google Scholar 

  32. Rayan A et al (2017) Nature is the best source of anticancer drugs: indexing natural products for their anticancer bioactivity. PLoS ONE 12(11):e187925. https://doi.org/10.1371/journal.pone.0187925

    Article  PubMed  PubMed Central  Google Scholar 

  33. Kumar A et al (2017) Potential anticancer role of colchicine – based derivatives: an overview. Anticancer Drugs 28(3):250–262

    Article  CAS  PubMed  Google Scholar 

  34. Cho JH et al (2017) Anticancer effects of colchicine on hypopharyngeal cancer. Anticancer Res 37(11):6269–6280

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. II. Med. Abteilung, NOE Kompentenzzentrum für Rheumatologie, Landesklinikum Korneuburg-Stockerau, Landstraße 18, 2000, Stockerau, Österreich

    J. Sautner

Authors
  1. J. Sautner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Sautner.

Ethics declarations

Interessenkonflikt

J. Sautner gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Dieser Beitrag bezieht sich auf einen Vortrag, der im Rahmen der Jahrestagung der österreichischen Gesellschaft für Rheumatologie im November 2017 stattfand. Das von Dr. Raimund Lunzer verfasste Contra-Statement findet sich ebenfalls in dieser Ausgabe von Rheuma Plus.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sautner, J. Colchicin zur Behandlung der Gicht. rheuma plus 17, 64–67 (2018). https://doi.org/10.1007/s12688-018-0174-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12688-018-0174-2

Schlüsselwörter

Keywords

Search

Navigation